Aclidinium bromide

Drug Profile

Aclidinium bromide

Alternative Names: Aclinidinium; Bretaris Genuair; Eklira Genuair; KRP-AB1102; LAS-34273; Tudorza Pressair; TudorzaGenuair

Latest Information Update: 15 Feb 2017

Price : $50

At a glance

  • Originator Almirall-Prodesfarma
  • Developer Allergan; Almirall S.A.; AstraZeneca; Daewoong Pharmaceutical; Forest Laboratories; Kyorin Pharmaceutical
  • Class Antiasthmatics; Antibronchitics; Bronchodilators; Quinuclidines; Small molecules; Tropanes
  • Mechanism of Action Muscarinic M3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Chronic obstructive pulmonary disease
  • No development reported Asthma

Most Recent Events

  • 13 Jan 2017 AstraZeneca and Parexel plan the phase III AVANT trial for Chronic obstructive pulmonary disease in India, Philippines, Taiwan and Vietnam (NCT03022097)
  • 13 Jan 2017 AstraZeneca and Parexel withdrew the phase III AVANT trial, prior to recruitment, for Chronic obstructive pulmonary disease in China (NCT03022097)
  • 01 Jan 2017 Phase-III clinical trials in Chronic obstructive pulmonary disease in Philippines (Inhalation) (NCT03022097)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top